| Title |
Disease progression and neuroscience
|
|---|---|
| Published in |
Journal of Pharmacokinetics and Pharmacodynamics, April 2013
|
| DOI | 10.1007/s10928-013-9316-2 |
| Pubmed ID | |
| Authors |
Nick Holford |
| Abstract |
The concepts of disease progression are discussed in the context of neurological disorders. The importance of understanding the time course of the response to inactive (placebo) treatment is discussed. Disease progression and response to placebo treatment both need to be considered before drug effects can be reliably identified. Criteria for distinguishing between symptomatic and disease modifying drug effects are proposed and used to interpret the results of clinical trials in pain, depression, schizophrenia, stroke, Alzheimer's disease and Parkinson's disease. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | 5% |
| Netherlands | 1 | 3% |
| Uruguay | 1 | 3% |
| Cuba | 1 | 3% |
| Australia | 1 | 3% |
| Belgium | 1 | 3% |
| Spain | 1 | 3% |
| United States | 1 | 3% |
| Unknown | 29 | 76% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 21% |
| Student > Ph. D. Student | 6 | 16% |
| Other | 5 | 13% |
| Professor > Associate Professor | 3 | 8% |
| Student > Master | 3 | 8% |
| Other | 5 | 13% |
| Unknown | 8 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 16% |
| Agricultural and Biological Sciences | 3 | 8% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Psychology | 2 | 5% |
| Other | 2 | 5% |
| Unknown | 11 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 April 2013.
All research outputs
#20,656,161
of 25,373,627 outputs
Outputs from Journal of Pharmacokinetics and Pharmacodynamics
#372
of 477 outputs
Outputs of similar age
#160,552
of 209,586 outputs
Outputs of similar age from Journal of Pharmacokinetics and Pharmacodynamics
#4
of 5 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 477 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 9th percentile – i.e., 9% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,586 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one.